News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F) Announces Phase III Data for Simeprevir Demonstrating Efficacy and Safety in Genotype 1 Hepatitis C Patients


12/20/2012 9:02:07 AM

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Simeprevir achieved SVR12 rates (viral cure) of 79% to 81% in the three pivotal phase III trials QUEST-1, QUEST-2 and PROMISE in genotype 1 hepatitis C patients.

The overall results demonstrate that simeprevir is safe and well tolerated with a safety profile of the simeprevir treatment arms similar to the placebo control.

A majority of the patients, 85-93%, were able to stop all treatment after 24 weeks.

Medivir AB (OMX: MVIR) today announced top-line results from three pivotal phase III trials examining the one pill, once-daily, investigational protease inhibitor, simeprevir (TMC435), administered with pegylated interferon and ribavirin.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES